Patents by Inventor Robert Douglas Knight

Robert Douglas Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR TREATING MALIGNANCIES
    Publication number: 20210100805
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
    Type: Application
    Filed: May 21, 2020
    Publication date: April 8, 2021
    Inventors: Vivek Saroj Kumar Chopra, Jorge DiMartino, Laurie A. Kenvin, Robert Douglas Knight, Kyle MacBerth, Krishnan Viswanadhan, Qiang Xu, Samuel V. Agresta
  • COMBINATION THERAPY FOR TREATING MALIGNANCIES
    Publication number: 20200405737
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and a DNA demethylating agent.
    Type: Application
    Filed: April 13, 2020
    Publication date: December 31, 2020
    Inventors: Samuel V. Agresta, Krishnan Viswanadhan, Jorge Dimartino, Vivek Saroj Kumar Chopra, Kyle J. Macbeth, Robert Douglas Knight, Laurie Kenvin, Qiang Xu
  • Combination therapy for treating malignancies
    Patent number: 10695352
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 30, 2020
    Assignees: Celgene Corporation, Agios Pharmaceuticals, Inc.
    Inventors: Vivek Saroj Kumar Chopra, Jorge DiMartino, Laurie A. Kenvin, Robert Douglas Knight, Kyle MacBeth, Krishnan Viswanadhan, Qiang Xu, Samuel V. Agresta
  • Combination therapy for treating malignancies
    Patent number: 10653710
    Abstract: Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 19, 2020
    Assignees: Agios Pharmaceuticals, Inc., Celgene Corporation
    Inventors: Samuel V. Agresta, Krishnan Viswanadhan, Jorge DiMartino, Vivek Saroj Kumar Chopra, Kyle J. MacBeth, Robert Douglas Knight, Laurie Kenvin, Qiang Xu
  • COMBINATION THERAPY FOR TREATING MALIGNANCIES
    Publication number: 20180303840
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Inventors: Vivek Saroj Kumar Chopra, Jorge DiMartino, Laurie A. Kenvin, Robert Douglas Knight, Kyle MacBeth, Krishnan Viswanadhan, Qiang Xu, Samuel V. Agresta
  • COMBINATION THERAPY FOR TREATING MALIGNANCIES
    Publication number: 20180296583
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and a DNA demethylating agent.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 18, 2018
    Inventors: Samuel V. Agresta, Krishnan Viswanadhan, Jorge DiMartino, Vivek Saroj Kumar Chopra, Kyle J. MacBeth, Robert Douglas Knight, Laurie Kenvin, Qiang Xu